Dalts posted " LinkedIn has a post from CHM referring to the first 3 patients of the CD17 trial. Cant post it for some reason. Two with stable disease, no tumour growth and T cell activity beyond 28 days."
Strange that Linkedin got that info and not the ASX. Maybe anns coming together with Ts & Cs. For those who don't know anything about Gastric cancers it might be disappointing but those who know that field will actually be very happy about it.
I rang Bell Potter and some other CR-sharkies, nobody got an invitation or details. Either they just tried to get rid of me or PH is finally bringing in serious LT money.
One thing never changed since the start of IMU and later CHM and RAD - it never gets boring even when the sp / companies have hit rock bottom.
Let's wait for the 2 or more anns.
CHM Price at posting:
0.7¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)